HOOKnew of price target increase to $4 per share.. Entered risking lod(red level).. Selling half at each target(green levels).. Trailing after second sell IF it works out
−0.8881USD
−64.915MUSD
14.249MUSD
74.366M
About HOOKIPA Pharma Inc.
Sector
Industry
CEO
Jörn Aldag
Website
Headquarters
New York
Employees (FY)
156
Founded
2011
ISIN
US43906K1007
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
HOOKIPA Pharma (USA: $HOOK) Look For An Imminent Eruption! 🌋HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II cli
HOOKIPA Pharma Inc 🧙HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and The
HOOK General/Rough Short Position Analysis Overall:
* Negative EPS
* June 7th conference @ASCO will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this
HOOK Ready to break HigherWe have classic up trend with more volume in the last 20 days. All signs of good news and push higher.
Hookia Pharma Soars on early stage FDA approval +++++++ HOT STOCK FOR FRIDAY +++++++++
Shares of Hookipa Pharma Inc. (HOOK) surged in after-hours trading Thursday after the company said the FDA approved an early stage trial of its treatment for human papilloma virus (HPV)-positive cancers.
The stock rose $2.46, or 37% to $9.14 in after-hours acti
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
